CNSX:DOSE

Stock Analysis Report

Executive Summary

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Share Price & News

How has Rapid Dose Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

DOSE

-1.0%

CA Life Sciences

0.2%

CA Market


1 Year Return

n/a

DOSE

16.2%

CA Life Sciences

3.5%

CA Market

Return vs Industry: Insufficient data to determine how DOSE performed against the Canadian Life Sciences industry.

Return vs Market: Insufficient data to determine how DOSE performed against the Canadian Market.


Shareholder returns

DOSEIndustryMarket
7 Day-4.2%-1.0%0.2%
30 Day-2.8%-5.6%-3.3%
90 Day-16.9%-5.4%-1.9%
1 Yearn/a16.4%16.2%7.3%3.5%
3 Yearn/a83.6%82.1%14.7%4.4%
5 Yearn/a109.8%100.4%26.2%7.7%

Price Volatility Vs. Market

How volatile is Rapid Dose Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Rapid Dose Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DOSE (CA$0.69) is trading below our estimate of fair value (CA$2.15)

Significantly Below Fair Value: DOSE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DOSE is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: DOSE is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DOSE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DOSE is overvalued based on its PB Ratio (17.4x) compared to the XN Life Sciences industry average (4.3x).


Next Steps

Future Growth

How is Rapid Dose Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

93.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DOSE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: DOSE is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: DOSE's loss is forecast to worsen by 0% next year.

Revenue vs Market: DOSE's revenue (67.5% per year) is forecast to grow faster than the Canadian market (5.5% per year).

High Growth Revenue: DOSE's revenue (67.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DOSE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Rapid Dose Therapeutics performed over the past 5 years?

-568.5%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if DOSE's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare DOSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DOSE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (45%).


Return on Equity

High ROE: DOSE has a negative Return on Equity (-470.2%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DOSE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DOSE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Rapid Dose Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: DOSE's short term assets (CA$2.6M) exceeds its short term liabilities (CA$1.7M)

Long Term Liabilities: DOSE has no long term liabilities


Debt to Equity History and Analysis

Debt Level: DOSE is debt free.

Reducing Debt: DOSE has not had any debt for past 5 years.


Balance Sheet

Inventory Level: DOSE has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DOSE's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DOSE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DOSE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Rapid Dose Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.9%industryaverage0.4%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DOSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DOSE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DOSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DOSE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DOSE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Rapid Dose Therapeutics's salary, the management and board of directors tenure and is there insider trading?

CA$412k

CEO Compensation


CEO

Mark Upsdell 0

0yrs

Tenure

CA$412,211

Compensation

Mr. Mark Andrew Upsdell is the Chief Executive Officer and Director of Rapid Dose Therapeutics Corp. and also serves as President. Mr. Upsdell leads RDT – Rapid Dose Therapeutics, with a unique combination ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Mark's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Insufficient data to compare Mark's compensation with company performance.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellCA$1,95005 Apr 19
Brian Howlett
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,500
Max PriceCA$0.78

Ownership Breakdown


Management Team

  • Ian Fodie (55yo)

    Chief Financial Officer

    • Tenure: 0.5yrs
  • Mark Upsdell

    President

    • Tenure: 0yrs
    • Compensation: CA$412.21k
  • Jason Lewis

    Senior VP of Business Development & Director

    • Tenure: 0yrs
    • Compensation: CA$192.12k
  • Kristina Shea

    Marketing & Communications Director

    • Tenure: 0yrs
  • Jorge Estepa

    Assistant Corporate Secretary

    • Tenure: 0yrs

Board Members

  • Brian Howlett

    Director

    • Tenure: 0yrs
  • Mark Upsdell

    President

    • Tenure: 0yrs
    • Compensation: CA$412.21k
  • Jason Lewis

    Senior VP of Business Development & Director

    • Tenure: 0yrs
    • Compensation: CA$192.12k

Company Information

Rapid Dose Therapeutics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rapid Dose Therapeutics Corp.
  • Ticker: DOSE
  • Exchange: CNSX
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$53.041m
  • Shares outstanding: 76.87m
  • Website: https://www.rapid-dose.com

Location

  • Rapid Dose Therapeutics Corp.
  • 1121 Walkers Line
  • Burlington
  • Ontario
  • L7N 2G4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DOSECNSX (Canadian National Stock Exchange)YesCommon SharesCACADDec 2018

Biography

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The company’s over the counter products include QuickStrip, a pro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:41
End of Day Share Price2019/10/22 00:00
Earnings2019/05/31
Annual Earnings2019/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.